Endocrine Abstracts

Objectives: To describe the metabolic and surgical outcomes of adult patients with craniopharyngioma undergoing extended transsphenoidal surgery (ETS). Secondary: to compare surgical outcomes with patients undergoing conventional transcranial surgery (CTS).Methods: Retrospective observational study. Adult patients with craniopharyngiomas undergoing ETS between 2015 and 2020 were included. Descriptive analysis was performed by obtaining median and quartil...

Intracranial tumors (IT) comprise a heterogenous group of neoplasias (e.g., pituitary/brain tumors and craniopharyngiomas), characterized by difficult diagnosis based on MRI, challenging prognostic predictors and lack of effective therapeutic strategies. In addition, these tumors are usually associated with neurological disorders and severe comorbidities (e.g., those associated with Cushing syndrome, Acromegaly, etc.), worsening the quality life of patients. In this context, s...

Methods: Descriptive retrospective study of the clinical outcomes and RNA expression in aggressive pituitary tumors treated with temozolomide. RNA expression was studied in tumor samples normalized to housekeeping genes including GH, POMC, PRL, αsub, FSH, LH, TSH, sst1, sst2, sst3, sst5, sst5b, sst5c, DR1, DR2T, DR2L, DR4, DR5, Ghrelin, In1-Ghrelin, GOAT, GHRR1b, AVPR1b, GHRH-R, GnRH-R, Ki-67, PTTG1, CRHR1.Results: Ten patients were treated. 30% (3)...

Introduction: Non-functioningpituitary adenomas (NFPAs) are of benign nature but a sizeable number of NFPAs show aggressive features. Surgery is not always effective in treating NFPAs and thus other therapeutic options are needed. Previous studies have reported that NFPAs express somastostatin receptors (SSTRs) and dopamine receptors (DRDs).Aim: To systematically analyze the expression of SSTRs and DRDs in a large cohort of clinically well-characterized ...

Pituitary tumours (PTs) constitute approximately 15% of all brain tumours, affecting up to 5% of the general population. The majority of PTs are hormonally active tumours (approximately 70%), resulting in significant comorbidities associated with hormone release. Furthermore, clinically non-functioning PTs (NFPTs, around 30%) exhibit mass effect-related comorbidities due to delayed diagnosis, despite lacking a link to hormone excess. Recent studies indicate that aberrant alter...